KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Total Debt (2016 - 2025)

Pfizer (PFE) has disclosed Total Debt for 17 consecutive years, with $61.7 billion as the latest value for Q3 2025.

  • On a quarterly basis, Total Debt fell 8.85% to $61.7 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $61.7 billion, a 8.85% decrease, with the full-year FY2024 number at $57.0 billion, down 20.71% from a year prior.
  • Total Debt was $61.7 billion for Q3 2025 at Pfizer, up from $57.5 billion in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $71.9 billion in Q4 2023 to a low of $34.3 billion in Q3 2022.
  • A 5-year average of $49.6 billion and a median of $57.0 billion in 2024 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: crashed 42.6% in 2021, then surged 100.64% in 2023.
  • Pfizer's Total Debt stood at $38.4 billion in 2021, then fell by 6.78% to $35.8 billion in 2022, then soared by 100.64% to $71.9 billion in 2023, then fell by 20.71% to $57.0 billion in 2024, then increased by 8.27% to $61.7 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Total Debt are $61.7 billion (Q3 2025), $57.5 billion (Q2 2025), and $62.1 billion (Q1 2025).